Evidence map›Paper›PMID 32761552›Full record

ArticleAdvances in therapy2020

Clinical and Economic Burden of Chronic Heart Failure and Reduced Ejection Fraction Following a Worsening Heart Failure Event.

Javed Butler, Laurence M Djatche, Baanie Sawhney, Sreya Chakladar, Lingfeng Yang, Joanne E Brady, Mei Yang

Open access · hybridAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
6.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 61 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Target doses of guideline-directed medical therapeutic agents predicts response to cardiac resynchronization therapy.Clinical research in cardiology : official journal of the German Cardiac Society · 2026
    Article
  8. Article
  9. Review
  10. Trajectory of health-related quality of life during and after hospitalisation due to worsening of heart failure.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025
    Article
  11. Article
  12. Observational
  13. Article
  14. Cost-Utility Analysis of Vericiguat in Heart Failure with Reduced Ejection Fraction After Worsening Heart Failure Events in China.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Javed ButlerUniversity of Mississippi Medical Center, Jackson, MS, USA. jbutler4@umc.edu.
Laurence M DjatcheMerck & Co., Inc., Kenilworth, NJ, USA.
Baanie SawhneyComplete Health Economics and Outcomes Research Solutions, North Wales, PA, USA.
Sreya ChakladarComplete Health Economics and Outcomes Research Solutions, North Wales, PA, USA.
Lingfeng YangMerck & Co., Inc., Kenilworth, NJ, USA.
Joanne E BradyMerck & Co., Inc., Kenilworth, NJ, USA.
Mei YangMerck & Co., Inc., Kenilworth, NJ, USA.
Merck & Co., Inc., Rahway, NJ, USA (United States) · USHealth Outcomes Solutions (United States) · USUniversity of Mississippi Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionA worsening heart failure event (WHFE) is defined as progressively escalating heart failure signs/symptoms requiring intravenous diuretic treatment or hospitalization. No studies have compared the burden of chronic heart failure with reduced ejection fraction (HFrEF) following a WHFE versus stable disease to inform healthcare decision makers.

methodsA retrospective study using the IBM

resultsOf 16,646 patients with chronic HFrEF, 26.8% developed a WHFE. Adjusted all-cause hospitalizations (0.16 vs. 0.02 PPPM, P < 0.0001), outpatient visits (3.54 vs. 2.73 PPPM, P < 0.0001), and emergency department visits (0.25 vs. 0.06 PPPM, P < 0.0001) were higher in patients following a WHFE than stable patients during the worsening assessment period. Similar differences in HCRU were observed between the two cohorts during the post-worsening assessment period. Mean total adjusted cost of care PPPM was $8657 in patients with HFrEF following a WHFE versus $2195 in stable patients during the worsening assessment period, and $6809 versus $2849, respectively, during the post-worsening assessment period.

conclusionHCRU and costs were significantly greater in patients with chronic HFrEF following a WHFE compared to those who remained stable, suggesting an unmet need to improve clinical and economic outcomes among these patients.

Indexed as

Cost of IllnessChronic DiseaseFemaleHeart FailureHospitalizationHumansMaleMiddle AgedRecurrenceRetrospective StudiesUnited StatesCost and cost analysis/economicsHealth care resource utilizationWorsening heart failure

Identifiers

PMID32761552
PMCPMC7444407
OpenAlexW3047295367

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.